Conditions: Chronic Lymphocytic Leukemia
Keywords: Relapsed chronic lymphocytic leukemia
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 21
Healthy volunteers: no

Brief summary:
The purpose of this research is to evaluate the safety and effectiveness of the drugs lenalidomide and ofatumumab in the treatment of chronic lymphocytic leukemia (CLL).

Detailed description:

Arms:
arm 1: Single arm, non randomized study

Ofatumumab, Lenalidomide: -Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1.

* Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28.
* Treatment to be administered for up to 6 cycles

Interventions: intervention 1: Ofatumumab intervention 2: Lenalidomide
Intervention descriptions: intervention 1: * Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1 for up to 6 cycles (28 day cycles)
* Treatment to be administered for up to 6 cycles intervention 2: -Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28 for up to 6 cycles (28 day cycles)

Protocol document: